Indoco Remedies Limited (NSE:INDOCO) filed the transcript of its Q1 FY27 earnings conference call on 4 August 2026, covering the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. The call was held on 28 July 2026 and featured the Managing Director, Joint Managing Director, and CFO.
Key Highlights
- Standalone operational revenue grew 5.8% year-on-year to INR4,081 million in Q1 FY27, while consolidated revenue rose 8.2% to INR4,662 million.
- Standalone EBITDA margin expanded sharply to 10.3% (INR422 million) in Q1 FY27 from 3.8% (INR148 million) in Q1 FY26.
- US business revenues surged 62.2% year-on-year to INR459 million, and API revenues grew 42.4% to INR521 million during the quarter.
- Baddi Unit III received EU-GMP certification from the German Health Authority, and Indoco Stability Center completed a USFDA pre-approval inspection with zero observations.
About the Company
Indoco Remedies Limited (NSE:INDOCO), headquartered in Mumbai, is a fully integrated pharmaceutical company engaged in manufacturing and marketing formulations and active pharmaceutical ingredients (API). The company operates manufacturing facilities in Goa, Baddi, and Chhatrapati Sambhajinagar, serving domestic and international markets including the US, Europe, and South Africa, and is listed in the Pharma sector.
Announcement in Detail
During Q1 FY27, domestic formulations revenues were INR2,040 million, broadly flat against INR2,028 million in Q1 FY26. International formulations grew 2.8% to INR1,451 million, with regulated markets up 19.3% to INR1,133 million. US revenues rose 62.2% to INR459 million, while Europe grew 2.5% to INR650 million. Emerging markets declined to INR317 million from INR461 million, attributed by management to timing-related primary billing in the prior March quarter.
The API segment grew 42.4% to INR521 million. The CRO and analytical solutions business, comprising AnaCipher CRO and Indoco Analytical Solutions, grew 36.2% to INR69 million. Management also disclosed the divestment of the Ophthalmic Division in India and agreed territories in Africa, described as a step to sharpen focus on core therapeutic areas. No update on outstanding USFDA plant matters was available at the time of the call.
Impact on Investors
Investors will note that consolidated EBITDA margin of 8.8% in Q1 FY27 compares with 4.1% in Q1 FY26, indicating a meaningful year-on-year improvement, though it remains below the Q4 FY26 consolidated margin of 10.9%. The filing shows standalone EBITDA recovered significantly from the prior-year quarter's 3.8%.
Shareholders will observe that the divestment of the Ophthalmic Division alters the company's business profile and revenue mix going forward. The pending USFDA response on plant matters, noted as unresolved during the call, remains a disclosed uncertainty that the filing does not resolve.
Sector / Market Context
India's pharmaceutical industry continues to be a significant export contributor, with formulation exports to regulated markets such as the US and Europe remaining a key growth avenue for mid-sized pharma companies. EU-GMP certifications and USFDA compliance are standard prerequisites for sustained access to these markets, as documented in SEBI exchange filings and industry body reports from Pharmexcil.